Press "Enter" to skip to content

Tag: Paxlovid

Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief, studies find

New findings from two studies have tied use of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) to a reduction in COVID-19 hospitalizations and death, as well as to faster resolution of symptoms and less use of healthcare resources.

Comments closed

Paxlovid tied to fewer COVID-19 hospitalizations, reduced risk of long COVID

A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.

Comments closed

Changes in Paxlovid coverage raises concerns about affordability, access in N.B.

New Brunswick has taken steps to make Paxlovid more affordable for some people at higher risk of becoming severely ill or dying from COVID-19, now that the federal government has stopped supplying the anti-viral medication to provinces for free.

But the drug designed to reduce symptoms from an infection and shorten the period of illness remains out of reach for many, either because of the cost of about $1,400 for a five-day course, a lack of timely access, or reduced eligibility.

Comments closed

Want To Prevent Long Covid? Should You Take Metformin Or Paxlovid?

Previously, I wrote about Paxlovid being underprescribed for treating acute Covid in patients at high risk for serious illness. The FDA granted an Emergency Use Authorization based on data showing that “Paxlovid significantly reduced the proportion of people with Covid-19 related hospitalization or death” by 88% compared to placebo.

In unvaccinated people, Paxlovid was also associated with a 26% lower risk of long Covid in a study by Ziyad Al-Aly.

The data on Paxlovid for those previously vaccinated is mixed. A smaller study from the University of California at San Francisco found no benefit in people who had been previously vaccinated.

Comments closed

The US Government Is Shutting Down A Key Covid Website

Tomorrow the US government agency responsible for biomedical and public health research, The National Institutes of Health, will shut down its Covid-19 ‘special populations’ website.

This site hosts a huge amount of information about how to treat covid and long covid in the immunocompromised and in people with HIV, cancer and similar immune supressing conditions – so-called ‘special populations.’

The site is going totally offline.

Comments closed

Video | Akiko Iwasaki on what causes long COVID, brain fog, the Yale Paxlovid study and long COVID treatments

What causes long COVID? Is long COVID dangerous? Who is most likely to get long COVID? Any pediatric long COVID news? What can be done for long term COVID?

Our guest is Akiko Iwasaki, PhD, Sterling Professor of Immunobiology at Yale University. AMA Chief Experience Officer Todd Unger hosts.

Comments closed

Long COVID still has no cure — so these patients are turning to research

When Lisa McCorkell got COVID-19 in March 2020, her symptoms were mild. Her physicians told her to isolate from others and that she would recover in a few weeks. But the weeks stretched into months and McCorkell, who was working on a master’s degree in public policy at the University of California, Berkeley, started having debilitating and bewildering symptoms: fatigue, dizziness and shortness of breath. Previously an avid runner, McCorkell found her heart racing from simple efforts.

She struggled to find an explanation, and soon realized that her physicians didn’t know any more about her condition than she did. To complicate matters, the limited availability of high-quality testing for the coronavirus SARS-CoV-2 in the early days of the pandemic left many of her doctors wondering whether her symptoms were really due to COVID-19 at all. “I didn’t have health-care providers that took me seriously,” McCorkell says. “That largely pushed me out of the health-care system.”

McCorkell turned instead to those who were experiencing the same puzzling symptoms and frustrations, joining a support group for people with what would eventually be called long COVID. As they compared notes, McCorkell and a handful of others — many of whom had research experience — realized that the information they were sharing might be helpful not only for those with long COVID, but also for those looking to study the condition. So, they founded a non-profit organization, called the Patient-Led Research Collaborative (PLRC), to design, provide advice on and even fund basic and clinical research into long COVID and other chronic illnesses.

Comments closed

Paxlovid to no longer be provided to provinces for free

The Public Health Agency of Canada (PHAC) is no longer paying for an antiviral pill used to treat COVID-19.

The PHAC said it will no longer procure Paxlovid, which is intended to be used after being diagnosed with COVID, for provinces and territories.

“The provinces and territories are responsible for determining how best to implement and manage the available supply of COVID-19 therapeutics, including Paxlovid,” a spokesperson for Health Canada said in a statement.

Comments closed

13 Things To Know About Paxlovid, the Latest COVID-19 Pill

Note: Information in this article was accurate at the time of original publication. Because information about COVID-19 changes rapidly, we encourage you to visit the websites of the Centers for Disease Control & Prevention (CDC), World Health Organization (WHO), and your state and local government for the latest information.

Paxlovid, an oral antiviral pill that can be taken at home, is the go-to treatment for COVID-19. If you are at high risk for severe disease from COVID, and you take it within the first five days of experiencing symptoms, it will lower your risk of getting so sick that you need to be hospitalized.

Comments closed

Paxlovid use tied to 84% lower risk of hospital care

University of North Carolina–Chapel Hill investigators report today that COVID-19 hospitalization risk was reduced by 84% among Paxlovid (nirmatrelvir and ritonavir) recipients in a large, diverse healthcare system during January to August 2022, when the Omicron strain was dominant.

The study appears in the Journal of Antimicrobial Chemotherapy. Paxlovid is authorized for use in US patients 12 years and older at risk for developing severe outcomes from COVID-19 infections. In early clinical trials, the use of the antiviral drug was associated with a relative risk reduction of 89% of disease progression to severe illness.

Comments closed

Once touted as a COVID-19 ‘game changer,’ Paxlovid is now a question mark for clinicians

If you catch the virus behind COVID-19 and you’re at a high risk of serious illness, there’s one major tool in a physician’s arsenal to keep you out of hospital: Paxlovid.

Pfizer’s antiviral drug was hailed as life-saving when it burst onto the scene midway through the pandemic. Clinical trials, conducted on people who’d never been vaccinated, showed it protected those vulnerable individuals from becoming dangerously sick, with a nearly 90 per cent reduction in the risk of hospitalization and death.

Comments closed

What to do if you get COVID

That moment you’ve been dreading has arrived (perhaps not for the first time). You or someone in your household woke up with a sore throat maybe, or a nagging cough, and you did the swab. Double red line. Dammit.

What to do now? “Pax and relax”? Sit it out and hope for the best? Go about your normal business (as an increasingly alarming number of “experts” seem to be advising)? Is it really all down to a matter of good luck, good genes and good health? Not really. The available science says that there are differences in outcomes for people based on the choices they make after they get COVID, provided they move quickly.

Comments closed

Canada enters 5th year of COVID-19. Are we falling short in treatment?

As Canada enters its fifth year navigating COVID-19, some experts and advocates are worried treatment options for the virus remain disappointingly inadequate.

Despite significant strides in understanding the virus, Jennifer Hulme, a 42-year-old emergency physician at the University Health Network in Toronto, says many Canadians suffering from long-term COVID-19 are left without many options.

She is one of them.

Comments closed

Early Paxlovid for COVID-19 halved death, hospitalization in new study

Starting the antiviral drug nirmatrelvir-ritonavir (Paxlovid) 0 or 1 day after COVID-19 symptom onset halved 28-day all-cause death and hospitalization rates compared with waiting 2 or more days, University of Hong Kong researchers report in Nature Communications.

Comments closed

Ivermectin warnings, a new COVID-19 antiviral, a changing threshold for care: These are the WHO’s updated treatment guidelines

The World Health Organization (WHO) has updated its guidelines for the treatment of COVID-19 patients, including categories of hospitalization risk to help doctors tailor treatment, and recommendations surrounding a new antiviral designed specifically to tackle the disease.

Comments closed

This drug was hailed as a COVID game-changer. Here’s what we know about Paxlovid today

The drug could help people at high risk, writes Dr. Lynora Saxinger. But COVID has changed. Here’s what you should know about the current risks and benefits.

Comments closed

Pfizer more than doubles price of lifesaving Covid-19 medication Paxlovid as US transitions out of pandemic phase

The price of the lifesaving Covid-19 antiviral medication Paxlovid will more than double as the United States transitions out of the emergency phase of the pandemic, drugmaker Pfizer said Wednesday.

Comments closed